Oral L-arginine therapy in patients with cystic fibrosis: a pilot study

H. Grasemann, K. Sroka, W. H. Nikolaizik, F. Ratjen (Essen, Germany)

Source: Annual Congress 2002 - Cystic fibrosis: new science, new epidemiology, new problems
Session: Cystic fibrosis: new science, new epidemiology, new problems
Session type: Thematic Poster Session
Number: 2112
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
H. Grasemann, K. Sroka, W. H. Nikolaizik, F. Ratjen (Essen, Germany). Oral L-arginine therapy in patients with cystic fibrosis: a pilot study. Eur Respir J 2002; 20: Suppl. 38, 2112

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Evaluation of adherence to medication treatment in pediatric patients with cystic fibrosis; a cross-sectional study
Source: International Congress 2019 – Treatments, adherence and psychosocial aspects of cystic fibrosis
Year: 2019

Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study
Source: Eur Respir J 2005; 25: 62-68
Year: 2005



Concomitant corticosteroid with anti-fibrotic therapy for idiopathic pulmonary fibrosis: a prospective multicenter study
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021


Self-cope cards: a pilot study with children affected by cystic fibrosis
Source: Virtual Congress 2020 – Challenges and updates in nursing care around the world
Year: 2020


Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study
Source: Eur Respir J 2012; 39: 772-775
Year: 2012


Exploring barriers to Pirfenidone adherence in patients with idiopathic pulmonary fibrosis: a prospective study
Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause
Year: 2020


Home intravenous antibiotic treatments in cystic fibrosis adult patients
Source: Eur Respir J 2002; 20: Suppl. 38, 158s
Year: 2002

Feasibility study of an intervention to increase treatment adherence in children with cystic fibrosis (CF)
Source: International Congress 2019 – Treatments, adherence and psychosocial aspects of cystic fibrosis
Year: 2019


Safety, tolerability and efficacy of intravenous aminophylline in adult patients with pulmonary exacerbations of cystic fibrosis
Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects
Year: 2014

Safety and efficacy of intravenous (IV) Fosfomycin in adult cystic fibrosis patients
Source: International Congress 2018 – Latest developments in cystic fibrosis
Year: 2018



Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial
Source: Eur Respir J, 57 (1) 2000348; 10.1183/13993003.00348-2020
Year: 2021



The experience of patients with cystic fibrosis during pulmonary exacerbations: a mixed-method study
Source: International Congress 2017 – Nursing practice across respiratory care pathways
Year: 2017

Inhaled mannitol as treatment for children with cystic fibrosis
Source: Annual Congress 2008 - The use of inhaled mannitol for assessing airway disease
Year: 2008


Efficacy and safety of oral sildenafil in cystic fibrosis childrenwith mild to moderate lung disease
Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis
Year: 2020

Interim data from a long-term safety, tolerability, and efficacy study of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonas aeruginosa infection
Source: International Congress 2014 – Cystic fibrosis: assessment and treatment
Year: 2014


Real-life data on the safety and tolerability of Pirfenidone versus Nintedanib in Idiopathic Pulmonary Fibrosis (IPF) patients: A single-centre retrospective study
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021


Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study
Source: Eur Respir J, 59 (2) 2100746; 10.1183/13993003.00746-2021
Year: 2022



A multicentre, observational cohort study to determine the efficacy and safety of lumacaftor/ivacaftor in patients with severe lung disease and cystic fibrosis
Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis
Year: 2019



Nasal high-flow therapy (NHFT) during exercise in patients with cystic fibrosis (CF): a randomized crossover trial
Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis
Year: 2020


Improvement in pulmonary function after IV antibiotic treatment in cystic fibrosis patients
Source: Eur Respir J 2002; 20: Suppl. 38, 342s
Year: 2002